ArticleEuropean journal of breast health2018
Symptoms Experience and Quality of Life in The Patients With Breast Cancer Receiving The Taxane Class of Drugs.
Article in European journal of breast health, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Effect of exercise before and/or during taxane-containing chemotherapy treatment on chemotherapy-induced peripheral neuropathy symptoms in women with breast cancer: systematic review and meta-analysis.Journal of cancer survivorship : research and practice · 2025Pooled it
- Effects of exercise on chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review and meta-analysis.Journal of cancer survivorship : research and practice · 2023Pooled it
- Quality of Life in Slovak Breast Cancer Survivors: A Cross-Sectional Study Using EORTC QLQ-C30 and BR23.Nursing reports (Pavia, Italy) · 2026Article
- Celecoxib pretreatment and nab-paclitaxel-associated acute pain syndrome in patients with breast cancer: a prospective, non-randomized controlled clinical study.International journal of surgery (London, England) · 2026Article
- Validation of the FACIT-Fatigue scale in patients with locally advanced or metastatic breast cancer.The oncologist · 2025Article
- Engineered Delivery Systems for Chinese Herbal Medicine in Peripheral Nerve Regeneration: Challenges, Advances, and Future Perspectives.Drug design, development and therapy · 2025Review
- Preliminary Analysis of Gut Microbiome and Gastrointestinal Symptom Burden in Breast Cancer Patients Receiving Chemotherapy Compared to Healthy Controls.Biological research for nursing · 2024Article
- Fatigue in patients with metastatic breast cancer undergoing single-agent taxane-based chemotherapy: a real-world data global network.Therapeutic advances in medical oncology · 2024Article
- Transition Metal-Decorated BACS omega · 2023Article
- Chemopreventive effects of Xiang Sha Liu Jun Zi Tang on paclitaxel-induced leucopenia and neuropathy in animals.Frontiers in pharmacology · 2023Article
- Curcumin as an Enhancer of Therapeutic Efficiency of Chemotherapy Drugs in Breast Cancer.International journal of molecular sciences · 2022Review
- Presence and Distress of Chemotherapy-Induced Peripheral Neuropathy Symptoms in Upper Extremities of Younger and Older Breast Cancer Survivors.Journal of patient-centered research and reviews · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study is to evaluate the symptoms experience and quality of life in patients with breast cancer receiving the taxane class of drugs. MATERIALS AND
methodsThis study was performed between November 2015 March 2016 in a chemotherapy unit of a university hospital with 48 patients, who agreed to participate in the study. The Memorial Symptom Rating Score (MSAS), Socio-demographic and Clinical Features Form, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Breast (EORTC QLQ- BR23) measures specific to breast cancer were used to obtain data.
resultsThe average age of the patients was 45.65. The majority of patients were treated with the paclitaxel/paclitaxel+trastuzumab treatment protocol (60.42%), and more than half (54.16%) of these patients were on 5 or 6 treatments. The symptoms patients experienced the most commonly included being sensitive, weakness or energy loss and pain. The symptoms they experienced severely were included fatigue and energy loss and being sensitive. The most distressing symptoms were pain, worry, numbness in hands and feet. The overall well-being score of the patients as per the quality of life findings was 46.18±11.66. While the lowest score for the functional scales was in the social function subscale (66.32±15.18), the highest score for the symptom scales was in the pain subscale (42.01±15.37). The lowest score for the EORTC QLQ-BR23 scales was in the sexual life subscale (20.83±20.19); the highest score was in the body appearance subscale (65.8±23.96).
conclusionThe results of the study are thought to be helpful for the oncology nurses in evaluating the patients in all aspects and in determining priorities for care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.